Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inetetamab Combined With Pyrotinib and Chemotherapy in HER2 Positive Metastatic Breast Cancer
NCT04681911Phase 2Unknown
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2020
- Primary completion
- Sep 2023
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inetetamab and pyrotinib in breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Objective Response Rate at 18 weeks. Status: unknown.
02
Drugs
inetetamabpyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04681911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04681911.